Dr. Eric H. Lee, M.D., PH.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 163
Licensed in California since 2014, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
CA license A132145 (first issued 2014; current) -
Hematology (Internal Medicine) Physician
CA license A132145 (first issued 2014; current) -
Medical Oncology Physician
CA license A132145 (first issued 2014; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Uci Health-Orange Orange, CA
- Memorialcare Orange Coast Medical Center Fountain Valley, CA
Medical groups
- Los Angeles Hematology-Oncology Medical Group (50 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 163
- Services billed
- 28,420
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 211 | 65 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 180 | 53 |
| Established patient office or other outpatient visit, 30-39 minutes | 33 | 24 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 27 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Fountain Valley, CA | 80 |
| Xtandi (enzalutamide) | 55 |
| Eliquis (apixaban) Other prescribers in Fountain Valley, CA | 47 |
| Ondansetron Hcl Other prescribers in Fountain Valley, CA | 47 |
| Dexamethasone Sodium Phosphate | 40 |
| Prochlorperazine Maleate Other prescribers in Fountain Valley, CA | 39 |
| Hydroxyurea Other prescribers in Fountain Valley, CA | 34 |
| Prednisone Other prescribers in Fountain Valley, CA | 34 |
| Abiraterone Acetate | 33 |
| Orgovyx (relugolix) | 32 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 62 companies reported 368 payments worth $27,248 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $11,189 |
|---|---|
| Eisai Inc. | $2,643 |
| Incyte Corporation | $2,392 |
| Janssen Biotech, Inc. | $1,637 |
| Novartis Pharmaceuticals Corporation | $1,487 |
| Lilly USA, LLC | $1,402 |
| Merck Sharp & Dohme LLC | $544 |
| Pfizer Inc. | $345 |
| Consulting Fee | $17,590 |
|---|---|
| Food and Beverage | $8,237 |
| Long term medical supply or device loan | $1,000 |
| Education | $421 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Consulting Fee DATROWAY · Oncology | $3,280 |
| AstraZeneca Pharmaceuticals LP Oct 27, 2025 | Consulting Fee TAGRISSO · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Oct 7, 2025 | Consulting Fee TAGRISSO · Oncology | $2,460 |
| AstraZeneca Pharmaceuticals LP Jun 12, 2025 | Consulting Fee | $2,460 |
| Eisai Inc. Aug 20, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,200 |
| Lilly USA, LLC Jun 27, 2025 | Consulting Fee | $1,250 |
| Janssen Biotech, Inc. Nov 3, 2025 | Consulting Fee RYBREVANT · Oncology | $1,080 |
| Seagen Inc. Jul 2, 2025 | Education in-kind | $99.95 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
All 26 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 30, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Incyte Corporation Dec 18, 2025 | Consulting Fee | $2,200 |
| Novartis Pharmaceuticals Corporation Nov 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Janssen Biotech, Inc. Nov 3, 2025 | Consulting Fee RYBREVANT · Oncology | $1,080 |
| AstraZeneca Pharmaceuticals LP Oct 27, 2025 | Consulting Fee TAGRISSO · Oncology | $2,460 |
| Novartis Pharmaceuticals Corporation Oct 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Oct 7, 2025 | Consulting Fee TAGRISSO · Oncology | $2,460 |
| Daiichi Sankyo Inc. Oct 7, 2025 | Education Enhertu · ONCOLOGY · in-kind | $77.99 |
| Novartis Pharmaceuticals Corporation Sep 19, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Aug 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Eisai Inc. Aug 20, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Novartis Pharmaceuticals Corporation Jul 25, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Seagen Inc. Jul 2, 2025 | Education in-kind | $99.95 |
| Lilly USA, LLC Jun 27, 2025 | Consulting Fee | $1,250 |
| Seagen Inc. Jun 23, 2025 | Education in-kind | $74.99 |
| AstraZeneca Pharmaceuticals LP Jun 12, 2025 | Consulting Fee | $2,460 |
| Novartis Pharmaceuticals Corporation Jun 12, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Janssen Biotech, Inc. Jun 2, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $77.99 |
| GlaxoSmithKline, LLC. Jun 2, 2025 | Education in-kind | $67.00 |
| Novartis Pharmaceuticals Corporation May 15, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Apr 25, 2025 | Education in-kind Company’s descriptionJournal Article | $23.10 |
| Novartis Pharmaceuticals Corporation Apr 24, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Mar 26, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Feb 21, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| Novartis Pharmaceuticals Corporation Jan 23, 2025 | Long term medical supply or device loan KISQALI · Oncology · in-kind | $83.33 |
| AstraZeneca Pharmaceuticals LP Jan 22, 2025 | Consulting Fee DATROWAY · Oncology | $3,280 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $283,699 in research payments for these studies, mostly to the institutions running them.
- A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05451810 - A randomized, open label phase 2/3 study comparing cobolimab + dostarl
GlaxoSmithKline, LLC. - An openlabel randomized phase 3 study of tucatinib in combination with trastuzumab and MFOLFOX6 versus MFOLFOX6 given with or without either cetuximab or bevacizumab as firstline treatment for subjects with HER2 metas…
Pfizer Inc. - A phase III,open label,sponsor blind,randomized study of dato dxd with or without osimertinib versus platinum based doublet chemotherapy for participants with egfr mutated locally advanced or metastatic non small cell…
AstraZeneca UK Limited - M23-362 - A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma
AbbVie Inc. - A Study to Evaluate the Optimization of the CRS Profile for Glofit+GemOx in R/R DLBCL
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.